Clinical Trial Information

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients with Modertately to Severely Active Ulcerative Colitis
  • Protocol Number: 12303
  • Status: Open
  • Treatment Type: Treatment
  • Phase: III
  • NCT ID: NCT03519945

Scope Information

Disease Site(s):
Other